General Information of Drug (ID: DMO913H)

Drug Name
PMID25482888-Compound-15 Drug Info
Cross-matching ID
PubChem CID
22387295
TTD Drug ID
DMO913H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saxagliptin DMGXENV Type-2 diabetes 5A11 Approved [2]
Sitagliptin DMGDKXN Cystic fibrosis CA25 Approved [3]
Alogliptin DM8WI3R Type-2 diabetes 5A11 Approved [4]
Linagliptin DMWFJTR Non-insulin dependent diabetes 5A11 Approved [5]
Vildagliptin DMYN59P Type-2 diabetes 5A11 Approved [6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [7]
Anagliptin DMJXIC9 Type-2 diabetes 5A11 Approved [8]
SaxaDapa FDC DMAPRWV Diabetic complication 5A2Y Phase 3 [9]
LC-150444 DM09RKB Type-2 diabetes 5A11 Phase 3 [10]
Dutogliptin DMM5VTA Type-2 diabetes 5A11 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [1]

References

1 DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
4 Clinical pipeline report, company report or official report of Takeda (2009).
5 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6 Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
9 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
10 Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
11 Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.